<p>先鋒集團有限公司 (IRSH)</p>
<p>表格 8.3 - 先鋒集團有限公司：Avadel Pharmaceuticals plc</p>
<p>2025 年 12 月 31 日/ 15:22 GMT/BST</p>
<p>Ap27</p>
<p>表格 8.3</p>
<p>愛爾蘭收購委員會</p>
<p>開盤位置披露/根據 1997 年愛爾蘭收購委員會法第 8.3 條的交易披露</p>
<p>規則，2022 年由持有相關證券 1% 或以上利益的人員提供</p>
<ol>
<li>關鍵信息</li>
</ol>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>- 披露者全名</td>
<td>先鋒集團有限公司</td>
</tr>
<tr>
<td>- 如果與 1(a) 不同，利益和空頭頭寸的所有者或控制者</td>
<td></td>
</tr>
<tr>
<td>提名或車輛公司的命名是不夠的。對於信託，必須命名受託人、設立人和受益人。</td>
<td></td>
</tr>
<tr>
<td>- 與本表相關的要約方/受要約方的名稱</td>
<td></td>
</tr>
<tr>
<td>請為每個要約方/受要約方使用單獨的表格</td>
<td>Avadel Pharmaceuticals plc</td>
</tr>
<tr>
<td>- 如果是與要約方/受要約方相關的豁免基金經理，請説明並指定要約方/受要約方的身份（注 1）</td>
<td></td>
</tr>
<tr>
<td>- 持有頭寸/進行交易的日期</td>
<td></td>
</tr>
<tr>
<td>對於開盤位置披露，請説明披露前的最新可行日期</td>
<td>2025 年 12 月 30 日</td>
</tr>
<tr>
<td>- 除上述 1(c) 中的公司外，披露者是否還在對任何其他要約方進行披露？</td>
<td></td>
</tr>
<tr>
<td>如果是現金要約或可能的現金要約，請説明 “N/A”</td>
<td>N/A</td>
</tr>
</tbody>
</table>
<ol>
<li>利益和空頭頭寸</li>
</ol>
<p>如果要披露的要約方或受要約方在 1(c) 中列出的相關證券的多個類別中存在利益和空頭頭寸，請為每個額外類別複製表 2。</p>
<p>Ap28</p>
<p>與披露相關的要約方或受要約方的相關證券的利益和空頭頭寸（如有）</p>
<p>（注 2）</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相關證券類別</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>（注 3）</td>
<td>0.01 美元普通股</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>利益</td>
<td>空頭頭寸</td>
<td></td>
<td></td>
</tr>
<tr>
<td>數量</td>
<td>%</td>
<td>數量</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>- 擁有和/或控制的相關證券</td>
<td>5,864,542</td>
<td>5.97%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- 現金結算衍生品</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- 股票結算衍生品（包括期權）和購買/出售協議</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>總計</td>
<td>5,864,542</td>
<td>5.97%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p>所有利益和所有空頭頭寸應予以披露。</p>
<p>包括認購新證券的權利和任何未平倉的股票結算衍生品頭寸（包括交易期權）或購買或出售相關證券的協議的選項詳細信息，應在補充表格 8 中提供。</p>
<ol>
<li>披露者的交易（如有）（注 4）</li>
</ol>
<p>如果在 1(c) 中列出的要約方或受要約方的多個類別的相關證券中有交易，請為每個額外類別複製表 3(a)、(b)、(c) 或 (d)（視情況而定）。</p>
<p>所有價格和其他貨幣金額的貨幣應予以説明。</p>
<p>(a) 購買和銷售</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相關證券類別</td>
<td>購買/銷售</td>
<td>證券數量</td>
<td>每單位價格</td>
</tr>
<tr>
<td>（注 5）</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.01 美元普通股</td>
<td>購買</td>
<td>610</td>
<td>21.54 美元</td>
</tr>
<tr>
<td>0.01 美元普通股</td>
<td>出售</td>
<td>306</td>
<td>21.54 美元</td>
</tr>
</tbody>
</table>
<p>Ap29</p>
<p>(b) 現金結算衍生品交易</p>
<ul>
<li>相關證券類別</li>
<li>產品描述，例如 CFD</li>
<li>交易性質，例如開立/平倉多頭/空頭頭寸，增加/減少多頭/空頭頭寸</li>
<li>參考證券數量（注 6）</li>
<li>每單位價格（注 5）</li>
</ul>
<p>(c) 股票結算衍生品交易（包括期權）</p>
<p>(i) 寫入、出售、購買或變更</p>
<ul>
<li>相關證券類別</li>
<li>產品描述，例如看漲期權</li>
<li>寫入、購買、出售、變更等。</li>
<li>與期權相關的證券數量（注 6）</li>
<li>每單位行使價格</li>
<li>類型，例如美式、歐式等。</li>
<li>到期日</li>
<li>每單位支付/收到的期權金額</li>
</ul>
<p>(ii) 行使</p>
<ul>
<li>相關證券類別</li>
<li>產品描述，例如看漲期權</li>
<li>行使/已行使</li>
<li>證券數量</li>
<li>每單位行使價格（注 5）</li>
</ul>
<p>(d) 其他交易（包括新證券的交易）（注 3）</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相關證券類別</td>
<td>不適用</td>
</tr>
<tr>
<td>交易性質</td>
<td></td>
</tr>
<tr>
<td>例如：認購、</td>
<td></td>
</tr>
<tr>
<td>轉換、行使</td>
<td></td>
</tr>
<tr>
<td>詳細信息</td>
<td></td>
</tr>
<tr>
<td>每單位價格（如</td>
<td></td>
</tr>
<tr>
<td>適用）</td>
<td></td>
</tr>
<tr>
<td>（注 5）</td>
<td></td>
</tr>
</tbody>
</table>
<p>Ap30</p>
<ol>
<li>其他信息</li>
</ol>
<p>(a) 賠償和其他交易安排</p>
<ul>
<li>任何賠償或期權安排的詳細信息，或與相關證券有關的任何協議或理解，無論是正式還是非正式，可能會誘使披露者與要約方或與要約方一致行動的任何人進行交易或避免交易。不可撤銷的承諾和意向書不應包括。如果沒有此類協議、安排或理解，請説明 “無”。</li>
<li>無</li>
</ul>
<p>(b) 與期權或衍生品相關的協議、安排或理解</p>
<ul>
<li>披露者與任何其他人之間的任何協議、安排或理解的完整詳細信息，涉及本表中提到的任何期權下的相關證券的投票權，或涉及本表中提到的任何衍生品的相關證券的投票權或未來的收購或處置。如果沒有，應説明。</li>
<li>無</li>
</ul>
<p>(c) 附件</p>
<ul>
<li>是否附有補充表格 8？</li>
<li>否</li>
</ul>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>披露日期</td>
<td>2025 年 12 月 31 日</td>
</tr>
<tr>
<td>聯繫人姓名</td>
<td>Shawn Acker</td>
</tr>
<tr>
<td>電話號碼</td>
<td>001-610-669-6713</td>
</tr>
</tbody>
</table>
<p>根據規則 8.3 的公開披露必須向監管信息服務進行。
監管公告的傳播由 EQS Group 傳輸。發行人對本公告的內容負全部責任。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>分類代碼：</td>
<td>RET - Avadel Pharmaceuticals plc</td>
</tr>
<tr>
<td>TIDM:</td>
<td>IRSH</td>
</tr>
<tr>
<td>LEI 代碼：</td>
<td>5493002789CX3L0CJP65</td>
</tr>
<tr>
<td>序列號：</td>
<td>413342</td>
</tr>
<tr>
<td>EQS 新聞 ID:</td>
<td>2253326</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>公告結束</td>
<td>EQS 新聞服務</td>
</tr>
</tbody>
</table>
<p><strong>免責聲明</strong></p>
<p>在商業背景下將新聞保存到數據庫或將新聞轉發給第三方，只有在獲得 EQS Group AG 事先書面同意的情況下才被允許。</p>

Avadel制藥

<p>先鋒集團（The Vanguard Group, Inc.）根據愛爾蘭收購委員會的規定披露了其在 Avadel 製藥（Avadel Pharmaceuticals plc）中的持股情況。截至 2025 年 12 月 30 日，先鋒集團持有 5,864,542 股普通股，佔公司總股本的 5.97%。最近的交易包括購買 610 股和出售 306 股，交易價格均為每股 21.54 美元。該披露於 2025 年 12 月 31 日發佈，未報告任何其他協議或安排</p>

<p>The Vanguard Group, Inc. (IRSH)</p>
<div class="lb-trans"><p>先鋒集團有限公司 (IRSH)</p>
</div><p>Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc</p>
<div class="lb-trans"><p>表格 8.3 - 先鋒集團有限公司：Avadel Pharmaceuticals plc</p>
</div><p>31-Dec-2025 / 15:22 GMT/BST</p>
<div class="lb-trans"><p>2025 年 12 月 31 日/ 15:22 GMT/BST</p>
</div><p>Ap27</p>
<div class="lb-trans"><p>Ap27</p>
</div><p>FORM 8.3</p>
<div class="lb-trans"><p>表格 8.3</p>
</div><p>IRISH TAKEOVER PANEL</p>
<div class="lb-trans"><p>愛爾蘭收購委員會</p>
</div><p>OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER</p>
<div class="lb-trans"><p>開盤位置披露/根據 1997 年愛爾蘭收購委員會法第 8.3 條的交易披露</p>
</div><p>RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE</p>
<div class="lb-trans"><p>規則，2022 年由持有相關證券 1% 或以上利益的人員提供</p>
</div><p>1. KEY INFORMATION</p>
<div class="lb-trans"><ol>
<li>關鍵信息</li>
</ol>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>- Full name of discloser</td>
<td>The Vanguard Group, Inc.</td>
</tr>
<tr>
<td>- Owner or controller of interests and short positions disclosed, if different from 1(a) <br/>The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.</td>
<td></td>
</tr>
<tr>
<td>- Name of offeror/offeree in relation to whose relevant securities this form relates <br/>Use a separate form for each offeror/offeree</td>
<td>Avadel Pharmaceuticals plc</td>
</tr>
<tr>
<td>- If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)</td>
<td></td>
</tr>
<tr>
<td>- Date position held/dealing undertaken <br/>For an opening position disclosure, state the latest practicable date prior to the disclosure</td>
<td>30 December 2025</td>
</tr>
<tr>
<td>- In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer? <br/>If it is a cash offer or possible cash offer, state “N/A”</td>
<td>N/A</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>- 披露者全名</td>
<td>先鋒集團有限公司</td>
</tr>
<tr>
<td>- 如果與 1(a) 不同，利益和空頭頭寸的所有者或控制者</td>
<td></td>
</tr>
<tr>
<td>提名或車輛公司的命名是不夠的。對於信託，必須命名受託人、設立人和受益人。</td>
<td></td>
</tr>
<tr>
<td>- 與本表相關的要約方/受要約方的名稱</td>
<td></td>
</tr>
<tr>
<td>請為每個要約方/受要約方使用單獨的表格</td>
<td>Avadel Pharmaceuticals plc</td>
</tr>
<tr>
<td>- 如果是與要約方/受要約方相關的豁免基金經理，請説明並指定要約方/受要約方的身份（注 1）</td>
<td></td>
</tr>
<tr>
<td>- 持有頭寸/進行交易的日期</td>
<td></td>
</tr>
<tr>
<td>對於開盤位置披露，請説明披露前的最新可行日期</td>
<td>2025 年 12 月 30 日</td>
</tr>
<tr>
<td>- 除上述 1(c) 中的公司外，披露者是否還在對任何其他要約方進行披露？</td>
<td></td>
</tr>
<tr>
<td>如果是現金要約或可能的現金要約，請説明 “N/A”</td>
<td>N/A</td>
</tr>
</tbody>
</table>
</div><p>2. INTERESTS AND SHORT POSITIONS</p>
<div class="lb-trans"><ol>
<li>利益和空頭頭寸</li>
</ol>
</div><p>If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.</p>
<div class="lb-trans"><p>如果要披露的要約方或受要約方在 1(c) 中列出的相關證券的多個類別中存在利益和空頭頭寸，請為每個額外類別複製表 2。</p>
</div><p>Ap28</p>
<div class="lb-trans"><p>Ap28</p>
</div><p>Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)</p>
<div class="lb-trans"><p>與披露相關的要約方或受要約方的相關證券的利益和空頭頭寸（如有）</p>
</div><p>(Note 2)</p>
<div class="lb-trans"><p>（注 2）</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class of relevant security <br/>(Note 3)</td>
<td>US$0.01 ordinary shares</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Interests</td>
<td>Short positions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number</td>
<td>%</td>
<td>Number</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>- Relevant securities owned and/or controlled</td>
<td>5,864,542</td>
<td>5.97%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Cash-settled derivatives</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Stock-settled derivatives (including options) and agreements to purchase/ sell</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>5,864,542</td>
<td>5.97%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相關證券類別</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>（注 3）</td>
<td>0.01 美元普通股</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>利益</td>
<td>空頭頭寸</td>
<td></td>
<td></td>
</tr>
<tr>
<td>數量</td>
<td>%</td>
<td>數量</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>- 擁有和/或控制的相關證券</td>
<td>5,864,542</td>
<td>5.97%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- 現金結算衍生品</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- 股票結算衍生品（包括期權）和購買/出售協議</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>總計</td>
<td>5,864,542</td>
<td>5.97%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</div><p>All interests and all short positions should be disclosed.</p>
<div class="lb-trans"><p>所有利益和所有空頭頭寸應予以披露。</p>
</div><p>Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.</p>
<div class="lb-trans"><p>包括認購新證券的權利和任何未平倉的股票結算衍生品頭寸（包括交易期權）或購買或出售相關證券的協議的選項詳細信息，應在補充表格 8 中提供。</p>
</div><p>3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)</p>
<div class="lb-trans"><ol>
<li>披露者的交易（如有）（注 4）</li>
</ol>
</div><p>Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.</p>
<div class="lb-trans"><p>如果在 1(c) 中列出的要約方或受要約方的多個類別的相關證券中有交易，請為每個額外類別複製表 3(a)、(b)、(c) 或 (d)（視情況而定）。</p>
</div><p>The currency of all prices and other monetary amounts should be stated.</p>
<div class="lb-trans"><p>所有價格和其他貨幣金額的貨幣應予以説明。</p>
</div><p>(a) Purchases and sales</p>
<div class="lb-trans"><p>(a) 購買和銷售</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class of relevant security</td>
<td>Purchase/sale</td>
<td>Number of securities</td>
<td>Price per unit<br/>(Note 5)</td>
</tr>
<tr>
<td>US$0.01 ordinary shares</td>
<td>Purchase</td>
<td>610</td>
<td>21.54 USD</td>
</tr>
<tr>
<td>US$0.01 ordinary shares</td>
<td>Sale</td>
<td>306</td>
<td>21.54 USD</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相關證券類別</td>
<td>購買/銷售</td>
<td>證券數量</td>
<td>每單位價格</td>
</tr>
<tr>
<td>（注 5）</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.01 美元普通股</td>
<td>購買</td>
<td>610</td>
<td>21.54 美元</td>
</tr>
<tr>
<td>0.01 美元普通股</td>
<td>出售</td>
<td>306</td>
<td>21.54 美元</td>
</tr>
</tbody>
</table>
</div><p>Ap29</p>
<div class="lb-trans"><p>Ap29</p>
</div><p>(b) Cash-settled derivative transactions</p>
<div class="lb-trans"><p>(b) 現金結算衍生品交易</p>
</div><ul>
<li>Class ofrelevantsecurity</li>
<li>Product description e.g. CFD</li>
<li>Nature of dealinge.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position</li>
<li>Number ofreference securities (Note 6)</li>
<li>Price per unit (Note 5)</li>
</ul>
<div class="lb-trans"><ul>
<li>相關證券類別</li>
<li>產品描述，例如 CFD</li>
<li>交易性質，例如開立/平倉多頭/空頭頭寸，增加/減少多頭/空頭頭寸</li>
<li>參考證券數量（注 6）</li>
<li>每單位價格（注 5）</li>
</ul>
</div><p>(c) Stock-settled derivative transactions (including options)</p>
<div class="lb-trans"><p>(c) 股票結算衍生品交易（包括期權）</p>
</div><p>(i) Writing, selling, purchasing or varying</p>
<div class="lb-trans"><p>(i) 寫入、出售、購買或變更</p>
</div><ul>
<li>Class of relevant security</li>
<li>Product description e.g. call option</li>
<li>Writing, purchasing, selling, varying etc.</li>
<li>Number of securities to which option relates (Note 6)</li>
<li>Exerciseprice per unit</li>
<li>Type e.g. American, Europeanetc.</li>
<li>Expiry date</li>
<li>Option moneypaid/ received per unit</li>
</ul>
<div class="lb-trans"><ul>
<li>相關證券類別</li>
<li>產品描述，例如看漲期權</li>
<li>寫入、購買、出售、變更等。</li>
<li>與期權相關的證券數量（注 6）</li>
<li>每單位行使價格</li>
<li>類型，例如美式、歐式等。</li>
<li>到期日</li>
<li>每單位支付/收到的期權金額</li>
</ul>
</div><p>(ii) Exercise</p>
<div class="lb-trans"><p>(ii) 行使</p>
</div><ul>
<li>Class of relevant security</li>
<li>Product description e.g. call option</li>
<li>Exercising/ exercised against</li>
<li>Number of securities</li>
<li>Exercise price per unit (Note 5)</li>
</ul>
<div class="lb-trans"><ul>
<li>相關證券類別</li>
<li>產品描述，例如看漲期權</li>
<li>行使/已行使</li>
<li>證券數量</li>
<li>每單位行使價格（注 5）</li>
</ul>
</div><p>(d) Other dealings (including transactions in respect of new securities) (Note 3)</p>
<div class="lb-trans"><p>(d) 其他交易（包括新證券的交易）（注 3）</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class of <br/>relevant <br/>security</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Nature of dealing <br/>e.g. subscription, <br/>conversion, exercise</td>
<td></td>
</tr>
<tr>
<td>Details</td>
<td></td>
</tr>
<tr>
<td>Price per unit (if <br/>applicable) <br/>(Note 5)</td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相關證券類別</td>
<td>不適用</td>
</tr>
<tr>
<td>交易性質</td>
<td></td>
</tr>
<tr>
<td>例如：認購、</td>
<td></td>
</tr>
<tr>
<td>轉換、行使</td>
<td></td>
</tr>
<tr>
<td>詳細信息</td>
<td></td>
</tr>
<tr>
<td>每單位價格（如</td>
<td></td>
</tr>
<tr>
<td>適用）</td>
<td></td>
</tr>
<tr>
<td>（注 5）</td>
<td></td>
</tr>
</tbody>
</table>
</div><p>Ap30</p>
<div class="lb-trans"><p>Ap30</p>
</div><p>4. OTHER INFORMATION</p>
<div class="lb-trans"><ol>
<li>其他信息</li>
</ol>
</div><p>(a) Indemnity and other dealing arrangements</p>
<div class="lb-trans"><p>(a) 賠償和其他交易安排</p>
</div><ul>
<li>Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer. Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”</li>
<li>none</li>
</ul>
<div class="lb-trans"><ul>
<li>任何賠償或期權安排的詳細信息，或與相關證券有關的任何協議或理解，無論是正式還是非正式，可能會誘使披露者與要約方或與要約方一致行動的任何人進行交易或避免交易。不可撤銷的承諾和意向書不應包括。如果沒有此類協議、安排或理解，請説明 “無”。</li>
<li>無</li>
</ul>
</div><p>(b) Agreements, arrangements or understandings relating to options or derivatives</p>
<div class="lb-trans"><p>(b) 與期權或衍生品相關的協議、安排或理解</p>
</div><ul>
<li>Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.</li>
<li>none</li>
</ul>
<div class="lb-trans"><ul>
<li>披露者與任何其他人之間的任何協議、安排或理解的完整詳細信息，涉及本表中提到的任何期權下的相關證券的投票權，或涉及本表中提到的任何衍生品的相關證券的投票權或未來的收購或處置。如果沒有，應説明。</li>
<li>無</li>
</ul>
</div><p>(c) Attachments</p>
<div class="lb-trans"><p>(c) 附件</p>
</div><ul>
<li>Is a Supplemental Form 8 attached?</li>
<li>No</li>
</ul>
<div class="lb-trans"><ul>
<li>是否附有補充表格 8？</li>
<li>否</li>
</ul>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of disclosure</td>
<td>31 December 2025</td>
</tr>
<tr>
<td>Contact name</td>
<td>Shawn Acker</td>
</tr>
<tr>
<td>Telephone number</td>
<td>001-610-669-6713</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>披露日期</td>
<td>2025 年 12 月 31 日</td>
</tr>
<tr>
<td>聯繫人姓名</td>
<td>Shawn Acker</td>
</tr>
<tr>
<td>電話號碼</td>
<td>001-610-669-6713</td>
</tr>
</tbody>
</table>
</div><p>Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.
Dissemination of a Regulatory Announcement, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.</p>
<div class="lb-trans"><p>根據規則 8.3 的公開披露必須向監管信息服務進行。
監管公告的傳播由 EQS Group 傳輸。發行人對本公告的內容負全部責任。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Category Code:</td>
<td>RET - Avadel Pharmaceuticals plc</td>
</tr>
<tr>
<td>TIDM:</td>
<td>IRSH</td>
</tr>
<tr>
<td>LEI Code:</td>
<td>5493002789CX3L0CJP65</td>
</tr>
<tr>
<td>Sequence No.:</td>
<td>413342</td>
</tr>
<tr>
<td>EQS News ID:</td>
<td>2253326</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>分類代碼：</td>
<td>RET - Avadel Pharmaceuticals plc</td>
</tr>
<tr>
<td>TIDM:</td>
<td>IRSH</td>
</tr>
<tr>
<td>LEI 代碼：</td>
<td>5493002789CX3L0CJP65</td>
</tr>
<tr>
<td>序列號：</td>
<td>413342</td>
</tr>
<tr>
<td>EQS 新聞 ID:</td>
<td>2253326</td>
</tr>
</tbody>
</table>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>End of Announcement</td>
<td>EQS News Service</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>公告結束</td>
<td>EQS 新聞服務</td>
</tr>
</tbody>
</table>
</div><p><strong>Disclaimer</strong></p>
<div class="lb-trans"><p><strong>免責聲明</strong></p>
</div><p>Saving the news in databases or any forwarding of the news to third parties in a commercial context or for commercial purposes is only permitted with the prior written consent of EQS Group AG.</p>
<div class="lb-trans"><p>在商業背景下將新聞保存到數據庫或將新聞轉發給第三方，只有在獲得 EQS Group AG 事先書面同意的情況下才被允許。</p>
</div>

表格 8.3 - Vanguard 集團公司：Avadel 製藥公司